Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (752)	1/19/2000 1:39:00 PM
From: Craig S. Owens	Read Replies (1) \| Respond to of 1494

Dr. John, thanks for sharing the good news. I just received an email from Freeedgar regarding NTI. I hope someone will read it and maybe they can help translate it to the masses. From what I read, we will be recieving a $2.1 million payment within 5 days. It also appears that they are making provisions to bring on a marketing partner by designating royalty split percentages. Obviously, my link didn't work but hopefully it will get you close to the release. (Copy it and paste it in your browser.) Go ahead Mr. Frieman and give us Dr. John's birthday present. We are waiting patiently. www.freeedgar.com/search/WL.asp?C=918112&F=10KSB/A&D=1/19/2000

To: Dr. John M. de Castro who wrote (752)	1/19/2000 9:35:00 PM
From: John McCarthy	Respond to of 1494

Hi John ....... Thank you for posting the P2 results for Memantine. This line is a KEEPER ......... <<This three-armed study comparing daily doses of placebo, 20 mg and 40 mg of Memantine, demonstrated statistically significantly less nocturnal pain intensity with 40 mg of Memantine compared to placebo after eight weeks of dosing. >> biz.yahoo.com Without doubt there are still significant risks ahead of us. Nonetheless, based on the P2 results I jumped in for an additional 2000 in the 4+ area. What has really stimulated me is this thought line: I hit homeruns in Biomatrix and QLTI because: In each of their cases what made their FDA walk thrus so easy was that their respective therapuetics were UNIQUE .... and .... addressed a serious lack of theraputices within their unique indications i.e. O/A and AMD ....... Given the size and scope of: painful peripheral neuropathy in diabetics ...... my simple-minded thinking is that if P3 holds up ....... the FDA is gonna want Memantine on the market ASAP ... Finally - AND MOST IMPORTANTLY - thanks again for all your postings on this company. If there is any searching or 'chase this down' that you might want me to do ... just yell. regards, John McCarthy